Results 171 to 180 of about 110,625 (292)

WHO classification of skin tumours: key updates in the fifth edition

open access: yesHistopathology, Volume 88, Issue 3, Page 555-568, February 2026.
This review article summarizes the key updates in the 5th edition of the WHO Classification of Skin Tumours. It provides an overview of the major changes and new entities specific to the skin section, covering areas such as epidermal, melanocytic, mesenchymal and other tumours. The 5th edition of the World Health Organization Classification of Tumours (
Gabrielle Goldman‐Lévy   +29 more
wiley   +1 more source

Rapid resolution of primary vulval adult Langerhans cell histiocytosis with very potent topical corticosteroids [PDF]

open access: bronze, 2009
Susan M. Foley   +4 more
openalex   +1 more source

Erdheim-Chester Disease in a Patient after Double Lung Transplantation for Pulmonary Langerhans Cell Histiocytosis

open access: bronze, 2021
Daria Kifjak   +5 more
openalex   +1 more source

GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis

open access: yesHistopathology, Volume 88, Issue 3, Page 698-709, February 2026.
We evaluated the diagnostic utility of GPNMB immunohistochemistry in LAM. GPNMB showed strong expression in LAM cells, while the differential diagnostic mimics showed no or only low expression. Based on its 100% sensitivity and specificity in our cohort, GPNMB is a highly reliable immunohistochemical marker for the diagnosis of LAM.
Fatime Szalai   +6 more
wiley   +1 more source

P1043: EFFICACY AND SAFETY OF TRAMETINIB IN ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS AND ERDHEIM-CHESTER DISEASE

open access: gold, 2023
Vitalii Latyshev   +3 more
openalex   +1 more source

MSC‐Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges—A Narrative Review

open access: yesInternational Journal of Dermatology, Volume 65, Issue 2, Page 257-272, February 2026.
ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy